Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care ...(//www.stemedica.com onclick linkClick( ...)

Date:4/15/2009

//www.stemedica.com" onclick="linkClick( this.href );" target="_blank" title="Stemedica Web Site">stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacture of best-in-class adult stem cells for use by approved research institutions and hospitals for pre-clinical and clinical studies. Within the United States, the Company is currently developing regulatory pathways for stroke, traumatic brain injury and wound repair. Outside the United States, Stemedica provides its adult stem cells to hospitals and research centers that are conducting studies under protocols approved by the appropriate regulatory agencies. These studies are focused on the treatment of neurodegenerative disease, sight restoration and wound repair. Stemedica is based in San Diego, California.

Media Contact for Stemedica:
Dave McGuigan at dmcguigan (at) stemedica (dot) com

###

Read the full story at http://www.prweb.com/releases/stemedica-burn-wound/partnership-applegate/prweb2322404.htm.

'/>"/>

Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Renowned Stem Cell Researcher Files Study Results With Stemedica
2. CIRM Completes Briefing Visit to Stemedica Cell Technologies
3. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
4. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
5. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
6. NexGen Biofuels Ltd Signs Letter of Intent for the Purchase of World Venture Management, Inc. Assets and the Sale of its Current Business
7. New Generation Biofuels Signs Sales Contract with Catoctin Mountain Growers to Supply up to 370,000 gallons of Renewable Biofuel
8. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
9. BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University
10. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
11. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company